Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th Street, Miami, FL, 33136, USA.
University of California San Francisco, San Francisco, CA, USA.
BMC Ophthalmol. 2021 Dec 20;21(1):440. doi: 10.1186/s12886-021-02212-x.
The authors sought to evaluate visual outcomes in patients with varying etiologies of neovascular glaucoma (NVG), who were treated with glaucoma drainage devices (GDD).
This was a retrospective case series of patients at a large academic teaching institution who had surgical intervention for neovascular glaucoma between September 2011 and May 2019. Eyes were included if there was documented neovascularization of the iris/angle with an intraocular pressure (IOP) > 21 mmHg at presentation. Eyes must also have been treated with surgical intervention that included a GDD. Primary outcome measure was visual acuity at the 1-year post-operative visit. Secondary outcome measure was qualified success after surgery defined by: pressure criteria (5 mmHg < IOP ≤ 21 mmHg), no re-operation for elevated IOP, and no loss of LP vision.
One hundred twenty eyes met inclusion criteria. 61.7% had an etiology of proliferative diabetic retinopathy (PDR), 23.3% had retinal vein occlusions (RVO), and the remaining 15.0% suffered from other etiologies. Of patients treated with GDD, eyes with PDR had better vision compared to eyes with RVO at final evaluation (p = 0.041). There was a statistically significant difference (p = 0.027) in the mean number of glaucoma medications with Ahmed eyes (n = 70) requiring 1.9 medications and Baerveldt eyes (n = 46) requiring 1.3 medications at final evaluation.
In our study, many patients with NVG achieved meaningful vision, as defined by World Health Organization (WHO) guidelines, and IOP control after GDD. Outcomes differed between patients with PDR and RVO in favor of the PDR group. Different GDD devices had similar performance profiles for VA and IOP outcomes. Direct prospective comparison of Baerveldt, Ahmed, and cyclophotocoagulation represents the next phase of discovery.
本研究旨在评估不同病因新生血管性青光眼(NVG)患者接受青光眼引流装置(GDD)治疗后的视力结局。
本研究为单中心回顾性病例系列研究,纳入 2011 年 9 月至 2019 年 5 月期间于某大型教学医院因 NVG 接受手术治疗的患者。纳入标准为:虹膜/房角新生血管伴有初次就诊时眼压(IOP)>21mmHg;接受包括 GDD 在内的手术干预。主要结局指标为术后 1 年的视力。次要结局指标为术后定义的合格成功,包括:眼压标准(5mmHg<IOP≤21mmHg)、无因眼压升高而再次手术、无 LP 视力丧失。
共纳入 120 只眼。61.7%的患者病因是增生性糖尿病视网膜病变(PDR),23.3%是视网膜静脉阻塞(RVO),其余 15.0%的患者病因不明。接受 GDD 治疗的患者中,PDR 患者的最终视力优于 RVO 患者(p=0.041)。最终评估时,Ahmed 组(n=70)和 Baerveldt 组(n=46)的平均青光眼药物数量分别为 1.9 种和 1.3 种,两组之间存在统计学差异(p=0.027)。
在本研究中,许多 NVG 患者通过 GDD 治疗实现了有意义的视力和眼压控制,符合世界卫生组织(WHO)的标准。PDR 患者的结局优于 RVO 患者。不同的 GDD 装置在视力和眼压结局方面的表现相似。贝伐单抗、 Ahmed 和睫状体光凝的直接前瞻性比较代表了下一阶段的研究。